Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460188 | 0.95 | NPC1 (0.45) | SCN4AMAPTL3MBTL1KMT2ANPC1 | |
| SCHEMBL4686964 | 0.87 | MCL1 (0.46) | MAPTL3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL4460441 | 0.86 | MCL1 (0.42) | MAPTL3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4460356 | 0.85 | LOXL2 (0.42) | NPC1RAB9AGRM5 | |
| SCHEMBL4458363 | 0.83 | MCL1 (0.38) | MAPTL3MBTL1NPC1RAB9AKDM4E | |
| SCHEMBL4469357 | 0.82 | MCL1 (0.42) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL4460360 | 0.82 | LTA4H (0.47) | SCN4AKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL4456543 | 0.82 | MCL1 (0.54) | MAPTL3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL4457387 | 0.82 | SCN4A (0.44) | SCN4AMAPTNPC1RAB9AGAA | |
| SCHEMBL4463577 | 0.82 | PPARG (0.40) | L3MBTL1NPC1RAB9AGRM5SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534805-B2 | Imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-19 | — | — | US | claimed |
| EP-1638943-B1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2008-08-06 | — | — | EP | claimed |
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-22 | — | — | US | claimed |
| JP-2007501267-A | — | — | 2007-01-25 | — | — | JP | claimed |
| EP-1638943-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-03-29 | — | — | EP | claimed |
| WO-2004106307-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-12-09 | — | — | WO | claimed |
| US-7534805-B2 | Imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-19 | — | — | US | disclosed |
| EP-1638943-B1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2008-08-06 | — | — | EP | disclosed |
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-22 | — | — | US | disclosed |
| EP-1638943-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004106307-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | MIF, MCL1, PPIP5K2 | SCN4A 4358/4885MAPT 2398/4885L3MBTL1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.